To access this element change to forms mode OFF
Grant Award View - GA71495
COmBining memantine And cholinesterase inhibitors in Lewy body dementia...
GA ID:
GA71495
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
29-Jan-2020
Publish Date:
24-Feb-2020
Category:
Health and Medical Research
Grant Term:
1-Mar-2020 to 28-Feb-2025
Value (AUD):
$1,218,120.05
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 19/20 1.1 Health and Medical Research
Grant Program:
National Institute for Health Research
Grant Activity:
COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT)
Purpose:
Many people who have been diagnosed with dementia with Lewy bodies or Parkinson’s disease dementia will be prescribed drugs known as acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine) to help with their symptoms. This research trial, known as COBALT, is designed to find out whether there is any benefit from taking the drug memantine as well. Australian and UK researchers are collaborating on this trial which will recruit eligible participants from both countries.
GO ID:
GO Title:
NHMRC-NIHR Collaborative Research Grant Scheme 2019 priorities for funding 2020
Internal Reference ID:
GNT1191765
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA